Reports

Embraer delivered solid Q4 2025 results with revenue rising 15% year over year to $2.65B, supported by higher aircraft deliveries and strong demand across business units. Net income reached $83.3M with EPS of $0.4549. The company ended the quarter with a record order backlog of $31.6B and generated strong adjusted free cash flow of $738.3M.

• Revenue increased 15% year over year driven by higher aircraft deliveries and strong demand.
• Record order backlog reached $31.6B, up more than 20% year over year.

Algonquin delivered a return to profitability in Q4 2025 driven by stronger regulated utility earnings, operational efficiencies and lower interest expense following debt repayment tied to asset sales. Adjusted earnings remained stable year-over-year while reported net earnings improved significantly from the prior-year loss.

• Q4 2025 revenue was $630700000, increasing from $584800000 in the prior year quarter.
• Net income was $29400000 compared with a net loss of $110200000 in Q4 2024.

Central Puerto reported a challenging fourth quarter with a significant decrease in net income and generation volumes, primarily driven by lower hydrology at the Piedra del Águila hydro complex and maintenance downtime. Despite these quarterly headwinds, the company achieved a 17% increase in full-year revenue and successfully transitioned thermal units to a new regulatory framework (Resolution No. 400/25).

• Adjusted EBITDA for Q4 2025 was US$ 84.7 million, a 16% decrease compared to the previous quarter.
• Total generation volumes fell 27% year-over-year to 3,957 GWh due to low water inflows and unplanned maintenance at Luján de Cuyo.

Tsakos Energy Navigation delivered a strong fourth quarter in 2025 driven by historically high tanker rates and strong fleet utilization. Revenue, operating income and net income increased significantly year-over-year as improved charter rates and lower voyage expenses boosted profitability.

• Q4 revenue increased to 222101000 from 188260000 in the prior-year quarter.
• Net income surged to 58011000 compared with 19271000 in Q4 2024.

Jade Biosciences remained a pre-revenue clinical-stage biotechnology company in Q4 2025. The company reported higher R&D and administrative expenses as it advanced multiple pipeline programs while maintaining a strong balance sheet with $336158000 in cash, cash equivalents and investments expected to fund operations into the first half of 2028.

• Net loss for Q4 2025 totaled 31900000 compared with 30100000 in the prior-year quarter.
• Research and development expenses increased to 28500000 from 17600000 as pipeline programs advanced.

Immuneering reported a significant improvement in its cash position following financing efforts, ending the year with $217 million. The company achieved positive Phase 2a clinical data in pancreatic cancer and secured regulatory alignment for its upcoming Phase 3 trial, while narrowing its quarterly net loss compared to the prior year.

• Observed 64% overall survival at 12 months in Phase 2a trial for first-line pancreatic cancer, significantly exceeding the 35% standard of care benchmark.
• Secured alignment with both FDA and EMA on the design of the pivotal Phase 3 MAPKeeper 301 trial.

Genesco delivered solid Q4 fiscal 2026 performance with sales growth and improved profitability supported by strong comparable sales, particularly at Journeys. Operating income increased year-over-year as expense leverage offset slightly lower gross margins amid promotional activity at Schuh and tariff-related pressures.

• Net sales increased 7% year-over-year to 799941000 with comparable sales growth of 9%.
• Net earnings rose to 47611000 compared with 34381000 in the prior-year quarter.

MarketWise delivered solid Q4 2025 results driven by strong billings growth and improved operating cash flow. While GAAP revenue declined compared to prior-year levels due to deferred revenue dynamics, billings surged 42% YoY, signaling stronger underlying demand and improved customer value through higher-priced offerings.

• Q4 net revenue was $83.4M while billings rose 42% YoY to $78.9M, signaling strong underlying sales momentum.
• Net income reached $14.0M with diluted EPS of $0.76 for the quarter.